390815-86-8

Basic information

• Product Name: Carbonic acid 4-[(S)-2-tert-butoxycarbonylamino-2-(2-methylamino-thiazol-4-yl)-ethyl]-phenyl ester tert-butyl ester
• Synonyms: Carbonic acid 4-[(S)-2-tert-butoxycarbonylamino-2-(2-methylamino-thiazol-4-yl)-ethyl]-phenyl ester tert-butyl ester
• CAS NO: 390815-86-8
• Molecular Weight: 449.571
• Mol File: 390815-86-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Carbonic acid 4-[(S)-2-tert-butoxycarbonylamino-2-(2-methylamino-thiazol-4-yl)-ethyl]-phenyl ester tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbonic acid 4-[(S)-2-tert-butoxycarbonylamino-2-(2-methylamino-thiazol-4-yl)-ethyl]-phenyl ester tert-butyl ester(390815-86-8)
• EPA Substance Registry System: Carbonic acid 4-[(S)-2-tert-butoxycarbonylamino-2-(2-methylamino-thiazol-4-yl)-ethyl]-phenyl ester tert-butyl ester(390815-86-8)

Safety Data

• Hazardous Substances Data: 390815-86-8(Hazardous Substances Data)

Upstream product

• 390815-84-6 carbonic acid 4-((S)-2-tert-butoxycarbonylamino-4-diazo-3-oxo-butyl)-phenyl ester tert-butyl ester 
• 20866-48-2 (S)-2-(tert-butoxycarbonylamino)-3-(4-(tert-butoxycarbonyloxy)phenyl)propanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 598-52-7 1-(methyl)-thiourea 
• 390815-85-7 carbonic acid 4-(4-bromo-2-tert-butoxycarbonylamino-3-oxo-butyl)-phenyl ester tert-butyl ester 

Downstream Products

• 390815-87-9 carbonic acid 4-((S)-2-tert-butoxycarbonylamino-2-thiazol-4-yl-ethyl)-phenyl ester tert-butyl ester 

Relevant articles and documents

Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: Inhibition of subgenomic hepatitis C virus RNA replicons in huh-7 cells

A previously disclosed series of non-nucleoside allosteric inhibitors of the NS5B polymerase of the hepatitis C virus (HCV) was optimized to yield novel compounds with improved physicochemical properties and activity in cell-based assays. Replacement of ionizable carboxylic acids with neutral substituents in lead compounds produced inhibitors with cellular permeability and antiviral activity in a cell-based assay of subgenomic HCV RNA replication (replicon EC50 as low as 1.7 μM. The improvement in potency in this ex vivo model of HCV RNA replication validates, in part, the mechanism by which this class of allosteric benzimidazole derivatives inhibits the polymerase and represents a significant step forward in the discovery of novel HCV therapeutics.